Cancer vaccines: between the idea and the reality

Whether vaccines are designed to prepare the immune system for the encounter with a pathogen or with cancer, certain common challenges need to be faced, such as what antigen and what adjuvant to use, what type of immune response to generate and how to make it long lasting. Cancer, additionally, presents several unique hurdles. Cancer vaccines must overcome immune suppression exerted by the tumour, by previous therapy or by the effects of advanced age of the patient. If used for cancer prevention, vaccines must elicit effective long-term memory without the potential of causing autoimmunity. This article addresses the common and the unique challenges to cancer vaccines and the progress that has been made in meeting them. Considering how refractory cancer has been to standard therapy, efforts to achieve immune control of this disease are well justified.

[1]  I. Frazer,et al.  Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. , 2002, Cancer research.

[2]  T. Whiteside,et al.  Recovery of ζ-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer , 2002, British Journal of Cancer.

[3]  Thierry Boon,et al.  Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.

[4]  R. McLendon,et al.  Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma , 2002, Neurosurgery.

[5]  D. Roses,et al.  Immunogenicity of a polyvalent melanoma antigen vaccine in humans , 1988, Cancer.

[6]  D. Carbone,et al.  Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  R. Offringa,et al.  Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine , 2001, The Journal of experimental medicine.

[8]  S. Gillies,et al.  T cell memory against colon carcinoma is long-lived in the absence of antigen. , 1999, Journal of immunology.

[9]  J. Brooks,et al.  Preneoplastic Prostate Lesions , 2001, Annals of the New York Academy of Sciences.

[10]  J. Timmerman,et al.  The history of the development of vaccines for the treatment of lymphoma. , 2000, Clinical lymphoma.

[11]  M. J. Tevethia,et al.  Mice with Spontaneous Pancreatic Cancer Naturally Develop MUC-1-Specific CTLs That Eradicate Tumors When Adoptively Transferred1 , 2000, The Journal of Immunology.

[12]  G. Schuler,et al.  Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells , 2002, The Journal of experimental medicine.

[13]  T. R. Mosrnann.  TH1 AND TH2 CELLS: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties , 2005 .

[14]  B. Moss,et al.  Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Berzofsky,et al.  A push–pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D J Schaid,et al.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.

[17]  K. Knutson,et al.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.

[18]  V. Apostolopoulos,et al.  Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice. , 2000, Vaccine.

[19]  Chun-Ming Lin,et al.  Activated human CD4+ T cells induced by dendritic cell stimulation are most sensitive to transforming growth factor-beta: implications for dendritic cell immunization against cancer. , 2002, Clinical immunology.

[20]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[21]  A. Sodhi,et al.  Age-Dependent Alterations in the Tumoricidal Functions of Tumor-Associated Macrophages , 1997, Tumor Biology.

[22]  Thomas K. Hoffmann,et al.  Identification of Cyclin B1 as a Shared Human Epithelial Tumor-Associated Antigen Recognized by T Cells , 2001, The Journal of experimental medicine.

[23]  J. Schlom,et al.  Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. , 1996, Human gene therapy.

[24]  David Gray,et al.  Immunological Memory and Protective Immunity: Understanding Their Relation , 1996, Science.

[25]  James Schultz.  Success of vaccine offers promise of cervical cancer prevention. , 2003, Journal of the National Cancer Institute.

[26]  H. Pandha,et al.  Immunotherapeutic potential of whole tumour cells , 2002, Cancer Immunology, Immunotherapy.

[27]  A. Ribas,et al.  alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. , 2001, Cancer research.

[28]  J. Schlom,et al.  Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer , 2005, Breast Cancer Research and Treatment.

[29]  J. Cerny,et al.  Repertoire of Antibody Response in Bone Marrow and the Memory Response Are Differentially Affected in Aging Mice1 , 2002, The Journal of Immunology.

[30]  Rustom Antia,et al.  Lineage relationship and protective immunity of memory CD8 T cell subsets , 2003, Nature Immunology.

[31]  V. Cerundolo,et al.  Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. , 2000, Cancer research.

[32]  J. Banchereau,et al.  Dendritic Cells Capture Killed Tumor Cells and Present Their Antigens to Elicit Tumor-Specific Immune Responses1 , 2000, The Journal of Immunology.

[33]  D. Roses,et al.  Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine , 1995, Cancer.

[34]  C. Leclerc,et al.  A recombinant virus‐like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant , 1998, European journal of immunology.

[35]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[36]  K. Blank,et al.  Decreased IL-2, IFN-gamma, and IL-10 production by aged mice during the acute phase of E55+ retrovirus infection. , 2002, Virology.

[37]  O. Finn,et al.  Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection1 , 2001, The Journal of Immunology.

[38]  J. Holmgren,et al.  Recent advances in mucosal vaccines and adjuvants. , 2002, Current opinion in immunology.

[39]  Yao-Tseng Chen,et al.  Cancer/testis antigens: an expanding family of targets for cancer immunotherapy , 2002, Immunological reviews.

[40]  Richard A. Miller,et al.  Age-Dependent Defects in TCR-Triggered Cytoskeletal Rearrangement in CD4+ T Cells1 , 2002, The Journal of Immunology.

[41]  I. Frazer,et al.  The number of long‐lasting functional memory CD8+ T cells generated depends on the nature of the initial nonspecific stimulation , 2002, European journal of immunology.

[42]  T. Eberlein,et al.  Mammaglobin-A is a tumor-associated antigen in human breast carcinoma. , 2003, Surgery.

[43]  M. Mitchell.  Perspective on allogeneic melanoma lysates in active specific immunotherapy. , 1998, Seminars in oncology.

[44]  D. Neuberg,et al.  Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Francesco M Marincola,et al.  Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? , 2002, Journal of the National Cancer Institute.

[46]  Piero Musiani,et al.  Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice , 2001, The Journal of experimental medicine.

[47]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[48]  P O Livingston,et al.  Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M. Lerch,et al.  Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. , 2001, JAMA.

[50]  M. Provinciali,et al.  Low effectiveness of DNA vaccination against HER-2/neu in ageing. , 2003, Vaccine.

[51]  J. Ahlers.  A push-pull approach to maximize vaccine efficacy : abrogating suppression with an IL-13 inhibitor while augmenting help with GM-CSF and CD40L , 2002 .

[52]  L. Paquet,et al.  A clinical report. , 1981, The Journal of the Dental Association of South Africa = Die Tydskrif van die Tandheelkundige Vereniging van Suid-Afrika.

[53]  K. Knutson,et al.  Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. , 2002, Blood.

[54]  A. Gambotto,et al.  Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[55]  M. Kovacsovics-Bankowski,et al.  A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules , 1995, Science.

[56]  T. Braun,et al.  A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  Jonathan J. Lewis,et al.  Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  S. Gendler,et al.  Spontaneous adenocarcinoma mouse models for immunotherapy. , 2001, Trends in molecular medicine.

[59]  V. Apostolopoulos,et al.  Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. , 1997, Journal of immunology.

[60]  I. Brockhausen,et al.  O-glycan biosynthesis in human colorectal adenoma cells during progression to cancer. , 1994, European journal of biochemistry.

[61]  J. Finke,et al.  Where have all the T cells gone? Mechanisms of immune evasion by tumors. , 1999, Immunology today.

[62]  O. Finn,et al.  Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[63]  L. Harris,et al.  First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. , 2001, European journal of cancer.

[64]  F. Sallusto,et al.  Functional subsets of memory T cells identified by CCR7 expression. , 2000, Current topics in microbiology and immunology.

[65]  J. Kirkwood,et al.  Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or Melanoma , 2002, The Journal of experimental medicine.

[66]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[67]  J. Schlom,et al.  Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. , 2001, Cancer research.

[68]  G. Riethmüller,et al.  Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma , 1994, The Lancet.

[69]  V. Apostolopoulos,et al.  MUC1 and breast cancer. , 1999, Current opinion in molecular therapeutics.

[70]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.

[71]  R. Levy,et al.  Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. , 1998, Blood.

[72]  M. Cheever,et al.  Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  P. Srivastava,et al.  Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. , 2002, Annual review of immunology.

[74]  J. Taylor‐Papadimitriou,et al.  Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1. , 2000, Cancer research.

[75]  L. Otvos,et al.  Complex Carbohydrates Are Not Removed During Processing of Glycoproteins by Dendritic Cells , 2002, The Journal of experimental medicine.

[76]  L. Falo,et al.  Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. , 1998, Journal of immunology.

[77]  J. Klijn,et al.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[78]  J. Kirkwood,et al.  Dendritic Cell/Peptide Cancer Vaccines: Clinical Responsiveness and Epitope Spreading , 2000, Immunological investigations.

[79]  R. Elashoff,et al.  Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[80]  J. M. van der Hulst,et al.  Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. , 2003, Cancer research.

[81]  R. Ahmed,et al.  Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. , 1998, Current opinion in immunology.

[82]  T. Giese,et al.  CpG-A Oligonucleotides Induce a Monocyte-Derived Dendritic Cell-Like Phenotype That Preferentially Activates CD8 T Cells1 , 2003, The Journal of Immunology.

[83]  S. Ménard,et al.  Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination , 2001, Gene Therapy.

[84]  C. Janeway,et al.  Lipoproteins take their toll on the host. , 1999, Current biology : CB.

[85]  R. Steinman,et al.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.

[86]  M. Boccadoro,et al.  Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. , 1999, Blood.

[87]  F. André,et al.  Vaccinology: past achievements, present roadblocks and future promises. , 2003, Vaccine.

[88]  D. Longo,et al.  Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. , 1992, Science.

[89]  S. H. van der Burg,et al.  Long lasting p53‐specific T cell memory responses in the absence of anti‐p53 antibodies in patients with resected primary colorectal cancer , 2001, European journal of immunology.

[90]  R H Hruban,et al.  Pancreatic Intraepithelial Neoplasia: A New Nomenclature and Classification System for Pancreatic Duct Lesions , 2001, The American journal of surgical pathology.

[91]  L. Grochow,et al.  Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  M. S. Singh,et al.  Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. , 1998, Advanced drug delivery reviews.

[93]  P. Ciborowski,et al.  Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells. , 1999, Cellular immunology.

[94]  P. Srivastava.  Immunotherapy of human cancer: lessons from mice , 2000, Nature Immunology.

[95]  D. Munn,et al.  Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection , 2002, International journal of cancer.

[96]  Michael S. Kuhns,et al.  CTLA-4: new insights into its biological function and use in tumor immunotherapy , 2002, Nature Immunology.

[97]  Frank O. Nestle,et al.  Dendritic cells: On the move from bench to bedside , 2001, Nature Medicine.

[98]  D. Whitcomb.  Genetic predispositions to acute and chronic pancreatitis. , 2000, The Medical clinics of North America.

[99]  Simon C Watkins,et al.  DNA–based immunization by in vivo transfection of dendritic cells , 1996, Nature Medicine.

[100]  D. Jäger,et al.  Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. , 1999, Cancer research.

[101]  E. Gehan,et al.  Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  H. Huland,et al.  Human Prostate Cancer Blocks the Generation of Dendritic Cells from CD34+ Hematopoietic Progenitors , 2001, European Urology.

[103]  M. Jutila,et al.  Mucosal addressin expression and binding‐interactions with naive lymphocytes vary among the cranial, oral, and nasal‐associated lymphoid tissues , 2002, European journal of immunology.

[104]  Guido Forni,et al.  Antitumor vaccines: is it possible to prevent a tumor? , 2002, Cancer Immunology, Immunotherapy.

[105]  M. Plummer,et al.  Strategies for HPV prevention. , 2002, Virus research.

[106]  H. Maguire,et al.  Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. , 2001, International journal of cancer.

[107]  G. Forni,et al.  Prophylactic cancer vaccines. , 2002, Current opinion in immunology.

[108]  M. Bertrand,et al.  An overview of the MAGE gene family with the identification of all human members of the family. , 2001, Cancer research.

[109]  D. Czerwinski,et al.  Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. , 1997, Blood.

[110]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[111]  D. Carbone,et al.  Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. , 1998, Journal of immunology.

[112]  Charles A. Janeway,et al.  Innate immunity: Lipoproteins take their Toll on the host , 1999, Current Biology.

[113]  H. Whittle,et al.  Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. , 1999, Vaccine.

[114]  H. Maguire,et al.  Treatment of metastatic melanoma with autologous, hapten‐modified melanoma vaccine: Regression of pulmonary metastases , 2001 .

[115]  Richard A. Miller,et al.  T Cell Subset Patterns That Predict Resistance to Spontaneous Lymphoma, Mammary Adenocarcinoma, and Fibrosarcoma in Mice1 , 2002, The Journal of Immunology.

[116]  R. Medzhitov.  CpG DNA: security code for host defense , 2001, Nature Immunology.

[117]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[118]  L. Burgart.  Colorectal polyps and other precursor lesions. Need for an expanded view. , 2002, Gastroenterology clinics of North America.

[119]  Gupta,et al.  Aluminum compounds as vaccine adjuvants. , 1998, Advanced drug delivery reviews.

[120]  A. Rópolo,et al.  CpG‐DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/c mice , 2002, Journal of leukocyte biology.

[121]  J. Schlom,et al.  Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. , 2002, Cancer research.

[122]  C. Janeway,et al.  The Toll receptor family and microbial recognition. , 2000, Trends in microbiology.

[123]  P. Musiani,et al.  Immunoprevention of colorectal cancer: a future possibility? , 2002, Gastroenterology clinics of North America.

[124]  J. Schlom,et al.  A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. , 1999, Journal of immunotherapy.

[125]  S. H. van der Burg,et al.  Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[126]  J. Bilsborough,et al.  Regulation of Mucosal Dendritic Cell Function by Receptor Activator of NF-κB (RANK)/RANK Ligand Interactions: Impact on Tolerance Induction , 2002, The Journal of Immunology.

[127]  H. Greenberg,et al.  CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. , 2000, Immunity.

[128]  G. Fleuren,et al.  Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. , 1999, European journal of cancer.

[129]  J. Stephenson.  Breast Cancer Risk , 2003 .

[130]  M. Sherman,et al.  A Preliminary Report , 1953 .

[131]  R. Zinkernagel,et al.  On differences between immunity and immunological memory. , 2002, Current opinion in immunology.

[132]  G. Dranoff.  GM‐CSF‐based cancer vaccines , 2002, Immunological reviews.

[133]  S. Gillies,et al.  Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[134]  E. Gilboa,et al.  Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells , 2002, Annals of surgery.

[135]  I. Shannon,et al.  A clinical report. Water-free stannous-fluoride gel and post-irradiation caries. , 1972, Journal of public health dentistry.

[136]  M. Croft,et al.  Defective T Cell Priming Associated with Aging Can Be Rescued by Signaling Through 4-1BB (CD137)1 , 2002, The Journal of Immunology.

[137]  T. Mak,et al.  The role of cytokines in classical Hodgkin lymphoma. , 2002, Blood.

[138]  E. Gilboa,et al.  Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA1 , 2001, The Journal of Immunology.

[139]  R. Elashoff,et al.  Prolonged Survival of Patients Receiving Active Immunotherapy With Canvaxin Therapeutic Polyvalent Vaccine After Complete Resection of Melanoma Metastatic to Regional Lymph Nodes , 2002, Annals of surgery.

[140]  R. Ahmed,et al.  Defective generation but normal maintenance of memory T cells in old mice , 2002, European journal of immunology.

[141]  R. Zinkernagel,et al.  Immunotherapy with Dendritic Cells Directed against Tumor Antigens Shared with Normal Host Cells Results in Severe Autoimmune Disease , 2000, The Journal of experimental medicine.

[142]  R. Henderson,et al.  Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. , 1995, Journal of immunology.

[143]  O. Finn,et al.  Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. , 2001, Cancer research.

[144]  J. Altman,et al.  Differentiating between Memory and Effector Cd8 T Cells by Altered Expression of Cell Surface O-Glycans , 2000, The Journal of experimental medicine.

[145]  S. Wilczynski,et al.  A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[146]  T. Braun,et al.  Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. , 2001, Cancer research.

[147]  M. Salgaller,et al.  Use of cellular and cytokine adjuvants in the immunotherapy of cancer , 1998, Journal of surgical oncology.

[148]  P. Gariglio,et al.  Interleukin‐10 promotes B16‐melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation , 2002, Immunology.

[149]  Sheue‐Rong Lin,et al.  Nationwide vaccination: a success story in Taiwan. , 2000, Vaccine.

[150]  P. Ciborowski,et al.  Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. , 1998, Cancer research.

[151]  M. Lotze,et al.  A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. , 1996, The Journal of surgical research.

[152]  S. Barratt-Boyes,et al.  Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[153]  E. Gilboa,et al.  Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. , 2002, The Journal of clinical investigation.

[154]  J. Berzofsky,et al.  Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs , 1990, Nature.

[155]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[156]  S. Aamdal,et al.  Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. , 2003, European journal of cancer.

[157]  V. Pennisi,et al.  Subcutaneous mastectomy data: A final statistical analysis of 1500 patients , 2005, Aesthetic Plastic Surgery.

[158]  R. Henderson,et al.  Human tumor antigens are ready to fly. , 1996, Advances in immunology.

[159]  E. Shevach,et al.  Cutting Edge: Control of CD8+ T Cell Activation by CD4+CD25+ Immunoregulatory Cells , 2001, The Journal of Immunology.

[160]  R. Kempf,et al.  Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. , 1988, Cancer research.

[161]  K. Imai,et al.  Comparative study for histology, proliferative activity, glycoproteins, and p53 protein between old and recent colorectal adenomas in Japan. , 2001, Cancer letters.

[162]  G. Bastert,et al.  Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow , 2001, Nature Medicine.

[163]  L. Hartmann,et al.  Risk-reduction mastectomy: clinical issues and research needs. , 2001, Journal of the National Cancer Institute.

[164]  H. Rammensee,et al.  Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. , 1999, Blood.

[165]  G. Dranoff,et al.  Cytokine-secreting tumor cell vaccines. , 2000, Current opinion in immunology.

[166]  R. Henderson,et al.  MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines , 1995, Immunological reviews.

[167]  T. Elliott,et al.  Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens , 2002, European journal of immunology.

[168]  L. Kanz,et al.  Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. , 2000, Blood.

[169]  E. Dimagno,et al.  Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. , 1997, Journal of the National Cancer Institute.